MIT reprograms natural killer cells into cancer killers inside the body

Overview

Updated 1 hour ago

MIT researchers have found a way to turn a patient's own natural killer (NK) immune cells into cancer-fighting cells without removing them. The technique uses lipid nanoparticles (LNPs) to deliver messenger RNA (mRNA) that instructs the cells to build chimeric antigen receptors (CARs), the targeting proteins used in CAR T therapies.

In mice, the method reprogrammed about 80 percent of targeted NK cells. It cleared tumors in three of five animals with aggressive melanoma and reversed liver damage in an autoimmune hepatitis model after one injection. Because the instructions arrive as mRNA, the change is temporary, and the experiments were in mice, so repeat dosing and human safety remain open questions.

Why it matters

If it works in people, an infusion could reprogram immune cells in place and replace a slow, costly manufacturing step.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

80%

Targeted NK cells reprogrammed

Share of targeted NK cells modified in mice after LNP infusion.

3 of 5

Mice in complete remission

Animals with aggressive melanoma that cleared tumors after treatment.

Injections to eradicate tumors

Doses needed in a humanized mouse model of T cell lymphoma.

Injection to reverse liver damage

Single dose that reduced autoreactive T cells in autoimmune hepatitis mice.

FDA-approved CAR NK therapies

No CAR NK cell therapy is approved for clinical use.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Daniel Anderson

Professor, MIT Department of Chemical Engineering; senior author

Leading the in-body CAR NK research

Robert Langer

David H. Koch Institute Professor, MIT; co-author

Co-author on the study

Yuang Chen

Postdoctoral researcher, MIT; lead author

Lead author on the study

Julia Monkovic

Graduate student, MIT; co-lead author

Co-lead author on the study

Haseeb Mughal

Graduate student, MIT; co-lead author

Co-lead author on the study

Organizations Involved

Massachusetts Institute of Technology (MIT)

Research university

Led the study

Private research university in Cambridge, Massachusetts, where the CAR NK study was conducted.

MIT Koch Institute for Integrative Cancer Research

Research institute at MIT

Home institution for senior authors

MIT cancer research center that houses senior author Daniel Anderson.

Timeline

October 2026 November 2026

2 events Latest: Today

November 2026
ScienceDaily publishes MIT summary of CAR NK results
Today Publication

Summary describes mouse results and the manufacturing shortcut.
Today
October 2026
Nature Biotechnology publishes in-body CAR NK study
Research

MIT team reports 80% NK transfection and tumor control in mice.
October 13th, 2026

Scenarios

First human trial of in-body CAR NK therapy opens

Possible Resolves by End of 2028

Discussed by: MIT researchers and ScienceDaily coverage

The mouse data would need to clear toxicology and manufacturing checks before a phase 1 study. A sponsor could use the same LNP platform to deliver CD19- or CD3-targeted CAR mRNA to NK cells in patients with B cell cancers or T cell-driven autoimmunity. Success would be a registered trial, not a published cure.

Independent lab replicates in-body NK reprogramming

Possible Resolves by End of 2027

Discussed by: Science Immunology review and MIT News coverage

The result matters more if another group can reproduce it with a different LNP design or mouse model. Independent replication would show the targeting strategy is not tied to one lab's particle formulation. Failure would leave the 80 percent transfection figure as a single-team result.

Repeat dosing becomes necessary in early human CAR NK testing

Likely Resolves by Q2 2028

Discussed by: MIT researchers and ScienceDaily coverage

The instructions arrive as mRNA, so the CAR is not permanently written into the cell's DNA. If early human testing shows CAR activity fading quickly, sponsors will need repeat infusions to maintain pressure on tumors or autoreactive T cells. That would raise cost and safety questions even if the first dose works.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

August 2017

First CAR T cell therapy approval (2017)

The Food and Drug Administration approved Kymriah, the first CAR T cell therapy, for a form of childhood leukemia. The treatment engineers a patient's T cells outside the body and returns them to attack cancer.

Then

The approval opened a new class of cancer treatment and a costly, patient-specific manufacturing process.

Now

CAR T therapies became standard options for several blood cancers, but they remain difficult to scale and are not used widely against T cell diseases.

Why this matters now

MIT's approach keeps the CAR idea but moves the engineering step inside the body, aiming to skip the lab manufacturing that made CAR T slow and expensive.

December 2020-August 2021

COVID-19 mRNA vaccines (2020-2021)

Pfizer-BioNTech and Moderna vaccines used lipid nanoparticles to deliver mRNA into human cells. The vaccines were given to billions of people.

Then

The vaccines showed that mRNA-LNP products could be manufactured at large scale and deployed in humans.

Now

The platform opened work on mRNA therapies beyond vaccines, including protein replacement and gene editing.

Why this matters now

The same basic delivery system is used here, but MIT's particles are coated to find NK cells rather than muscle or liver tissue.

August 2018

Patisiran and LNP delivery to the liver (2018)

The Food and Drug Administration approved patisiran, the first RNA interference drug delivered with lipid nanoparticles. The particles carried RNA to the liver to silence a disease-causing protein.

Then

The approval showed that LNPs could deliver RNA to a specific organ in patients.

Now

LNP delivery became a practical route for RNA medicines, though most approved uses still target the liver.

Why this matters now

MIT's study is a test of whether LNPs can be aimed at a harder target: circulating immune cells rather than liver tissue.